000			01750 a2200457 4500
005			20250514011911.0
264		0	_c20020123
008			200201s 0 0 eng d
022			_a0149-2918
024	7		_a10.1016/s0149-2918(01)80117-x _2doi
040			_aNLM _beng _cNLM
100	1		_aHarris, S I
245	0	0	_aUpper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo. _h[electronic resource]
260			_bClinical therapeutics _cSep 2001
300			_a1422-8 p. _bdigital
500			_aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAnalgesics, Non-Narcotic _xadverse effects
650	0	4	_aAnti-Inflammatory Agents, Non-Steroidal _xadverse effects
650	0	4	_aCyclooxygenase 2
650	0	4	_aCyclooxygenase 2 Inhibitors
650	0	4	_aCyclooxygenase Inhibitors _xadverse effects
650	0	4	_aDouble-Blind Method
650	0	4	_aFemale
650	0	4	_aGastric Mucosa _xdrug effects
650	0	4	_aHumans
650	0	4	_aInfusions, Parenteral
650	0	4	_aIsoenzymes
650	0	4	_aIsoxazoles _xadverse effects
650	0	4	_aKetorolac _xadverse effects
650	0	4	_aMale
650	0	4	_aMembrane Proteins
650	0	4	_aNaproxen _xadverse effects
650	0	4	_aPeptic Ulcer _xchemically induced
650	0	4	_aProstaglandin-Endoperoxide Synthases
700	1		_aKuss, M
700	1		_aHubbard, R C
700	1		_aGoldstein, J L
773	0		_tClinical therapeutics _gvol. 23 _gno. 9 _gp. 1422-8
856	4	0	_uhttps://doi.org/10.1016/s0149-2918(01)80117-x _zAvailable from publisher's website
999			_c11509538 _d11509538